1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,024 | 0,028 | 09:46 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Genflow Biosciences reports positive anti-ageing dog trial results | 1 | Alliance News | ||
| Di | Genflow: Gentherapie-Studie an Hunden erreicht primären Endpunkt | 2 | Investing.com Deutsch | ||
| Di | Genflow meets primary endpoint in aged dog gene therapy trial | 2 | Investing.com | ||
| Di | Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met | 169 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Di | Genflow Biosciences - Primary Endpoint in SLAB Clinical Trial Met | 1 | RNS | ||
| Mo | Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser | 198 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces... ► Artikel lesen | |
| Mo | Genflow Biosciences - Appointment of Investor Relations Adviser | - | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.08. | Baidu Wenku Wangpan's GenFlow Announces Chinese Name 'Kuku AI' | 25 | AASTOCKS | ||
| 03.08. | Genflow Biosciences PLC Announces Patent Update | 267 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 03.08. | Genflow Biosciences - Patent Update | 1 | RNS | ||
| 13.07. | Genflow meldet positive Studiendaten bei Hunden und sichert sich LNP-Partnerschaft | 1 | Investing.com Deutsch | ||
| 13.07. | Genflow reports positive dog trial data, secures LNP partnership | 1 | Investing.com | ||
| 13.07. | Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary | 407 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year... ► Artikel lesen | |
| 13.07. | Genflow Biosciences - Mid-Year Operational and Corporate Summary | - | RNS | ||
| 29.06. | Genflow Biosciences PLC Announces Result of AGM | 296 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce... ► Artikel lesen | |
| 29.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
| 22.06. | Genflow Biosciences PLC Announces Participation at BIO International Convention 2026 | 277 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad... ► Artikel lesen | |
| 22.06. | Genflow Biosciences - Participation at BIO International Convention 2026 | - | RNS | ||
| 17.06. | Genflow präsentiert im Oktober Daten zur Gentherapie bei alternden Hunden | 2 | Investing.com Deutsch | ||
| 17.06. | Genflow to present aged dog gene therapy data in October | 4 | Investing.com |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 45,415 | +0,92 % | Why CRISPR Therapeutics Stock Rocked the Market Last Month | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,125 | +2,37 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| DENALI THERAPEUTICS | 18,500 | +0,38 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| VOYAGER THERAPEUTICS | 2,872 | +4,66 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| BIOAGE LABS | 7,495 | +0,67 % | BioAge Labs, Inc.: BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 0,890 | +1,71 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| BIOPHYTIS | 0,046 | 0,00 % | Biophytis Announces Completion Of €5.3 Million Capital Increase To Fund Its Phase 2 Trial In Obesity | ||
| SERINA THERAPEUTICS | 2,100 | 0,00 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 | - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data - - Pharmacokinetic observations at the lowest dose... ► Artikel lesen | |
| LONGEVERON | 6,755 | +1,73 % | Longeveron Announces 1-for-10 Reverse Stock Split | MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related... ► Artikel lesen | |
| CG ONCOLOGY | 72,00 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ERASCA | 16,040 | +0,06 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| RELAY THERAPEUTICS | 18,890 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| HARMONY BIOSCIENCES | 41,100 | 0,00 % | Harmony Biosciences stellt auf Cantor-Konferenz erweiterte Wachstumsstrategie vor | ||
| ADMA BIOLOGICS | 9,390 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,48 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,019 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.